Cascade screening for familial hypercholesterolemia: Practical consequences

Familial Hypercholesterolemia (FH) is an autosomal dominant disorder mainly caused by mutations in the LDLR gene, resulting in elevated serum cholesterol levels and elevated risk of premature cardiovascular disease (CVD). Timely treatment with lipid lowering medication can lower the risk of CVD to the same level of the normal population. Currently the incidence of FH is estimated at 1 in 240 persons in the Caucasian population. A diagnosis of FH can be made on the basis of clinical criteria (including LDL cholesterol and family history) or DNA testing. When a mutation is known within a family an unequivocal diagnosis can be made by DNA testing in family members at any age. Genetic cascade screening is a cost-effective way to identify patients and prevent CVD. Between 1994 until 2014 a nationwide and government subsidized cascade screening program functioned to identify FH patients in the Netherlands. During this time more than 28,000 patients with FH have been identified and entered in a central, national database. Since 2014 cascade screening has been integrated in the regular Dutch health care system. Screening, counseling and treatment are now integrated in the care as a whole of FH patients and families, coordinated by the treating physician, while the national FH database is still maintained. However, since cascade screening by actively approaching family members cannot be applied anymore because of new regulations within the healthcare system, the number of family members participating in the cascade screening program, has plummeted. With this review we would like to highlight the practical consequences of implementing and executing a cascade screening program with a special focus on the lessons learned in the Netherlands. (C) 2017 Elsevier B.V. All rights reserved